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Mitochondrial dysfunction manifests in many forms during childhood. There is no effective therapy for the
condition; hence symptomatic therapy is the only option. The effect of symptomatic therapy are not well known.
We present clinical course, diagnosis and effect of current treatments for six children suffering from mitochondrial
encephalomyopathy identified by clinical demonstrations, brain MRI findings and DNA mutations. Two were male
and four were female. Their age ranged between 2 and 17 years. Skeletal muscle biopsies were obtained in three
and one showed misshaped and enlarged mitochondria under electron microscope. mtDNA mutation frequency
was >30%. Five children were diagnosed with MELAS (mitochondrial encephalopathy, lactic acidosis, and strokelike
episodes) and one with Leigh’s syndrome (LS). All were given cocktail and symptomatic treatments. One of the five
MELAS children died from severe complications. The other four MELAS children remain alive; four showed
improvement, and one remained unresponsive. Of the four who showed improvement, two do not have any
abnormal signs and the other two have some degree of motor developmental delay and myotrophy. The LS child
is doing well except for ataxia. Until better therapy such as mitochondrial gene therapy is available, cocktail and
symptomatic treatments could at least stabilize these children.
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Mitochondrial disorders are a group of metabolic diseases,
which may cause any symptom, may present at any age,
have harmful effects on any tissue and occur by any inherit-
ance pattern [1]. Mitochondrial dysfunction causes a huge
burden of disability. Mitochondrial encephalopathy, lac-
tic acidosis, and stroke-like episodes (MELAS) is a more
frequently identified mitochondrial disorder.
Currently, there is no effective remedy for mitochondrial
disorders. Potential therapies such as stem cell transplant-
ation and gene therapy are only in preliminary stages, mak-
ing cocktail (i.e. supplementation with carnitine, coenzyme
Q10, thiamine, L-arginine, folate, etc.) and symptomatic
treatments the only options for clinical treatment. A
combination of nutraceutical compounds often referred to
as “mitochondrial cocktail” is based upon a rational attempt
to target the final common pathways of mitochondrial* Correspondence: Lu139762@163.com
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reproduction in any medium, provided the ordysfunction and provision of alternative energy sources [2].
In this context, we present clinical diagnostic aspects, cock-
tail and symptomatic treatments, efficacy of such treatment
and course of mitochondrial encephalomyomathy (ME) in
six children.Cases
Six children were identified with ME at Haikou People’s
Hosptial, Hainan, China between October 2006 and
October 2012 by clinical demonstrations, brain MRI
and blood DNA analysis. Three of the six ME children were
subjected to skeletal muscle biopsies. The mtDNA from
blood samples was analyzed in all patients. Five children
were diagnosed with MELAS and one child with Leigh’s
syndrome. All patients were given cocktail and symp-
tomatic treatments, and followed up for one to six years.
Cocktail therapy included carnitine (20 mg/kg/d), coenzyme
Q10 (5 mg/kg/d), L-arginine (0.1 g/kg/d), adenosine
triphosphate (ATP)(80–140 mg/d), vitamin C (0.5-1.0 g/d),
monosialotetrahexosylganglioside (40–80 mg/d), folateal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lu and Huang Italian Journal of Pediatrics 2013, 39:60 Page 2 of 5
http://www.ijponline.net/content/39/1/60(1 mg/d), creatine phosphate (1–3 g/d), thiamine (VB1)
(25 mg/d), riboflavin (VB2) (25 mg/d) and vitamin B6
(25 mg/d). The treatment was initiated in the hospital and
continued at home following discharge. Symptomatic treat-
ments, such as anti-epilepsy, anti-arrhythmia, anti-infection
and antilactic acidosis that are important in stabilizing the
disease condition were also given when needed. These pa-
tients were admitted to hospital when there were severe
complications requiring specific treatment, e.g. mechanic
ventilation support in an intensive care unit for respiratory
failure. During follow ups, we observed these patients’ clin-
ical course (Figure 1) brain images, effect of treatment and
outcome. The outcome was mainly based on three aspects:
improvement, ineffectiveness, and death.
Table 1 shows clinical characteristics and laboratory find-
ings of six ME children. The mean age of onset of ME was
7.2 ± 4.5 years (range, 1-12 years). The mean age at first
hospital admission was 8.0 ± 4.4 years (range, 1–13 years).
Two children were male and four were female. All patients
had symptoms and signs indicative of mitochondrial disor-
ders on admission, mostly demonstrating neuromuscular
disorders. Most of the patients had neuromuscular and
sensory organ disorders (including seizures, motor ab-
normality, deafness, eye problem, etc.) either at onset or
on admission, two patients had gastrointestinal disorders
and one had signs of cardiac arrhythmia. The serum lactic
acid levels were markedly elevated in all six patients indicat-
ing severe mitochondrial involvement. The serum creatine
kinase (CK) levels were also abnormally high suggesting the
involvement of mostly the muscles that are rich in mito-
chondria. In brain MRI abnormal signals were often seen in
occipital, parietal and temporal lobes in MELAS and the
sites of these signals changed with time. The changing
pattern from restricted involvement of bilateral cerebral
peduncle and brainstem tegmental areas to involvement
of basal ganglia area was characteristically seen in patients
with Leigh’s syndrome. On electroscope findings of skeletal
muscle biopsies, one patient (patient 1) had abnormal
mitochondria that is typical of a mitochondrial disorder; two
others (patient 3 and patient 4) demonstrated atrophic
myopathies with no obvious variations of mitochondria.
Table 2 shows mtDNA mutations in patients and their
mothers. All six patients had a DNA mutation frequencyFigure 1 Clinical courses of six patients. Note: Vertical axis: patients 1–6of more than 30%. The mean was 48.2% ± 15.5%. The
carrier mother (with no clinical manifestation) of patient 1
and patient 2 with MELAS had a low mutation frequency
of 3.8% and the carrier mother of patient 6 with LS had a
higher mutation frequency of 30%.
Special features of two siblings (patient 1 and patient 2):
Patient 1 and patient 2 are siblings, they were both
diagnosed with MELAS, and their mothers are carriers.
The diagnosis was based on the clinical manifestations,
laboratory findings (Table 1), typical brain MRI findings
(patient 1, Table 1 and Figure 2), biceps brachii biopsy
findings (patient 1 and Figure 3), and family mtDNA
mutations (Figure 4). The two siblings were given cocktail
and symptomatic treatments for two years after diagnosis.
However, patient 1 died after two years of treatment
because of severe complications of massive gastrointestinal
haemorrhage and shock following recurrence of a stroke-
like episode. Patient 2 was stabilized after one year of treat-
ment, but she still could not speak, and had amyotrophy
and severe mobility limitations.
Figure 1 shows clinical courses of mitochondrial diseases
in six patients. Three patients were admitted to hospital at
the onset of the disease, while the other three admitted with
some time delay (about one to two years after disease onset).
Until the latest follow up in October 2012, five patients were
stabilized with cocktail and symptomatic treatments
and, one was free from all symptoms. One patient died
at home due to recurrence of a stroke-like episode with
severe complications.
Discussion
Mitochondrion is a vital organelle and its dysfunction
can cause various diseases at various levels in cells, tis-
sues, organs and systems. The final result of mitochon-
drial diseases is the failure for the cell to produce energy
in the form of adenosine triphosphate (ATP) leading to
multisystem dysfunction [3]. These diseases start in
childhood and progress subsequently with significant
suffering that result in heavy burdens on affected fam-
ilies. Mitochondrial encephalomyopathy is one of the
most frequent clinical phenotype of childhood mito-
chondrial disorders [4]. For several decades, cocktail and
symptomatic treatments remain the only seemingly, horizontal axis: clinical courses in different calendar years.
Table 1 Clinical characteristics and laboratory findings on admission




















6.7 118 Patchy T1 and T2 abnormal
signals in right temporal,
occipital and parietal lobes
and left parietal lobes.
2 1 Mobility limitation 3 Mobility and speaking
limitation, amyotrophy,
monophasia
4.58 276 Spotted T1 and T2 abnormal






4.5 602 Multiple patchy T1 and T2
abnormal signals in bilateral
cerebellar hemisphere, both
occipital lobes and right
parietal lobe.




2.8 766 Large patchy T1 and T2
abnormal signals in left
temporo-occipito-parietal
lobes.
5 11 Pitting edema,
tachycardia, blurred
vision, seizures
11 Pitting edema, tachycardia,
blurred vision, seizures
3.0 277 Large patchy T1 and T2
abnormal signals in bilateral
temporo-occipito-parietal
lobes.





3.9 138 Abnormal signals in bilateral
cerebral peduncle and
brainstem tegmental area.
Note: The mean level of lactic acid was 4.25 ± 1.41 mmol/L, the mean level of creatine kinase was 362.83 ± 262.73 IU/L. These brain MRI findings represent those
at admission, subsequent brain MRI during follow up showed different degree of changes in different sites.
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disease with these treatments is unknown.
Mitochondrial diseases occur due to mtDNA mutations
or deletions. Other mitochondrial diseases due to mito-
chondrial structural defect, nDNA mutations, intergenomic
signaling defects between nDNA and mtDNA, etc. are not
easily diagnosed [6]. For many years the most frequently
reported mitochondrial disease has been MELAS [7].
Early diagnosis of mitochondrial diseases and effective









1 MELAS m.3243A>G 34% 3.8%
2 MELAS m.3243A>G 53% 3.8%
3 MELAS m.3243A>G 47.4% N
4 MELAS m.3243A>G 47.6% N




MELAS =mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes.clinical examination and search for typical symptoms [8]
is the key that leads to initial diagnostic work-up. Be-
cause of highly variable phenotypes of mitochondrial
diseases, they are often undiagnosed or misdiagnosed
as other neuromuscular diseases, developmental delay,
encephalopathy, etc. Six patients we described above also
had presentations easily leading to misdiagnosis such
as vomiting, neuromuscular dysfunction, epilepsy, ataxia,
speech delay and ocular disorders. They had a mean time
delay for diagnosis of 1 (1.1 ± 0.8) year.
The neuroimaging often give early clues for diagnosis of
ME. The brain MRI findings of above six patients showed
characteristic abnormal signals in occipital, temporal,
parietal lobes and basal ganglia. Typical “protean”
manifestations with time were also characteristically
observed. Skeletal muscle biopsy and mutational studies
help in the diagnosis in the absence of straightforward
radiological findings. Observation of mitochondrial ultra-
structure in a muscle under electron microscope is useful
although all patients may not show the changes [8]. In
the present case series one of the three muscle biopsied
patients showed misshaped and enlarged mitochondria
indicative of mitochondrial dysfunction. The clinical
phenotype, MELAS in the above five cases corresponded
Figure 2 Brain MRI (FLAIR, fluid-attenuated inversion recovery) of patient 1: (A) taken one year before admission;: Abnormal signals in
the left occipital, parietal, and temporal lobes (arrowheads) and a cyst (arrow) in the right parietal area. (B) Abnormal MRI signals shifted
to the right side (arrowheads) at admission from previous left side. Symmetrical lesions at the lenticular nuclei (arrow) were also observed.
(C) These abnormalities were dramatically decreased (arrowheads) after 30 days cocktail treatment in hospital.
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32.3% to 53% (mean value, 42.9% ± 9.2%). Leigh’ syndrome
had m.13513G >A mutation with a mutation frequency of
75%. This aspect shows that there is no direct relationship
between the clinical severity and the mutation frequency.
The threshold mutation rate of MELAS usually reportedFigure 3 Electron microscopy examination of the biceps brachii
muscle: (A) Biopsy from patient 1 on admission shows
misshaped mitochondria (arrows), and enlarged mitochondria
with inclusion bodies (asterix). (B) Biopsy from a control subject.in the literature is >70-80% [9]. Quantitative analyses of
the mutation among siblings (Figure 4) showed different
mutation loads in blood and urine [in patient 1: 34%
and 59.7% respectively and in patient 2: 53% and 75.3%
respectively]. The mutation loads in blood is lower than
in urine. Usually the blood specimen is used to study
mutation frequency instead of urine because of the more
complicated processing of the urine sample.
The serum biomarkers, such as lactic acid, ammonia,
creatine, and glucose are useful to some extent though
they lack specificity. The high levels of lactic acid and
creatine in all six patients reflected metabolic disorder
and muscle damage.
Currently, cocktail therapy enhancing respiratory
chain function [9] and symptomatic therapy [4] remainFigure 4 Mutations in family member by restriction fragment
length polymorphism analysis using a 294-base pair fragment,
amplified by polymerase chain reaction (PCR). The figure shows
the digest result of blood and urine samples of patient 1 and 2, their
mother and the negative control. After digestion of the target gene,
two fragments (182 bp and 112 bp) were generated, using a blood
and a urine samples from three members of the family (3, 9, 15
were blood samples and 4,10,16 were urine samples of patient 1;
1, 7, 13 were blood samples and 2, 8, 14 were urine samples of
patient 2; 5, 11, 17 were blood samples and 6, 12,18 were urine
samples of mother; 19,20 were controls). The figure confirms the
A3243G mutation point in amplified products of these samples.
The gene in the mother’s blood sample was almost not digested
(with a mutation frequency of only 3.8%). The gene in the negative
control (i.e. that does not contain this mutation) was not digested.
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We achieved a stabilization rate of 83.3% (5/6) with these
treatment options.
Symptomatic treatment focused on the following symp-
toms: lactic acidosis, epilepsy, respiratory failure, cardiac
arrhythmia, malnutrition and abnormalities of muscle
tone. We used sodium bicarbonate to treat lactic acid-
osis when the patient had recurrent stroke-like epi-
sodes and presented with shock. To treat epilepsy, we
used carbamazepine or diazepam instead of sodium
valproate, which has been associated with liver disease.
Invasive or non-invasive mechanic ventilation was used
for respiratory failure. Regular anti-arrhythmia regimen
will delay progression of cardiomyopathy and heart failure.
Because of bulbar or pseudobulbar complications of
mitochondrial disease, we used nasogastric tube feeding
in small children with dysphagia and increased risk of
aspiration pneumonia. We cooperated with physiother-
apists to treat the patients with dystonia and spasticity,
which gave some improvement.
Conclusion
In conclusion, from our clinical study, we believe cocktail
and symptomatic treatments, at present, can stabilize
childhood mitochondrial diseases to some extent. The
long term benefits of these treatment modalities however
need to be explored further.
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